Acute Respiratory Distress Syndrome Market to Grow Positively at a Paltry CAGR During the Study Period | Edesa Biotech, Boehringer Ingelheim/Genentech, BioMarck Pharmaceuticals, Direct Biologics, expected to boost the market

DelveInsight's "Acute Respiratory Distress Syndrome - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Acute Respiratory Distress Syndrome market share of the individual therapies, current and forecasted Acute Respiratory Distress Syndrome market size from 2020 to 2034 segmented by seven major markets. The report also offers current Acute Respiratory Distress Syndrome therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Respiratory Distress Syndrome market.
Download sample pages @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening condition characterized by sudden and widespread inflammation in the lungs, leading to severe respiratory distress and hypoxemia (low blood oxygen levels). ARDS is associated with a high mortality rate and often requires intensive medical care.

Causes

ARDS can be triggered by a variety of conditions and factors, including:

1. Sepsis:
- A systemic infection that leads to widespread inflammation and can cause ARDS.

2. Pneumonia:
- Both bacterial and viral pneumonia can lead to ARDS by causing severe lung inflammation.

3. Trauma:
- Physical injury to the chest or lungs can result in ARDS.

4. Aspiration:
- Inhalation of foreign substances, such as gastric contents, can cause inflammation and ARDS.

5. Pulmonary Embolism:
- Blockage of a pulmonary artery by a blood clot can lead to ARDS.

6. Toxic Inhalation:
- Exposure to harmful substances or chemicals, such as smoke or industrial fumes, can damage lung tissue.

7. Pancreatitis:
- Severe inflammation of the pancreas can lead to ARDS.

8. Drug Reactions:
- Certain medications or drug overdoses can induce ARDS.

9. Autoimmune Diseases:
- Conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis can contribute to ARDS through inflammation and immune system dysfunction.

10. COVID-19:
- The SARS-CoV-2 virus, which causes COVID-19, has been associated with severe cases of ARDS.

Signs and Symptoms

ARDS typically presents with:

- Severe Shortness of Breath: Difficulty breathing that develops rapidly, often within hours to days.
- Rapid Breathing (Tachypnea): Increased respiratory rate.
- Labored Breathing: Use of accessory muscles and retractions.
- Low Oxygen Levels (Hypoxemia): Reduced oxygen saturation in the blood, often despite supplemental oxygen.
- Cough: May be present, often producing minimal or no sputum.
- Confusion or Altered Mental Status: Due to low oxygen levels affecting the brain.
- Cyanosis: Bluish discoloration of the lips, face, or extremities due to insufficient oxygen.

Diagnosis

Diagnosing ARDS involves:

1. Clinical Evaluation:
- Medical History: Reviewing recent illnesses, trauma, or exposures.
- Physical Examination: Observing signs of respiratory distress, abnormal lung sounds, and other clinical findings.

2. Laboratory Tests:
- Arterial Blood Gas (ABG) Analysis: To assess blood oxygen levels, carbon dioxide levels, and acid-base balance.
- Blood Tests: To identify underlying causes such as infection, inflammation, or organ dysfunction (e.g., complete blood count (CBC), metabolic panel).

3. Imaging Studies:
- Chest X-ray: Shows bilateral lung infiltrates consistent with ARDS and helps rule out other conditions.
- CT Scan of the Chest: Provides more detailed images of lung involvement and can help identify specific patterns or complications.

4. Other Diagnostic Tests:
- Pulmonary Function Tests: Assess lung function and the severity of respiratory impairment.
- Bronchoscopy: May be performed to visualize the airways and obtain lung samples if an infectious or inflammatory cause is suspected.

Treatment Options

Treatment for ARDS focuses on addressing the underlying cause, supporting respiratory function, and managing complications:

1. Supportive Care:
- Mechanical Ventilation: Often required to support breathing, with strategies such as low tidal volume ventilation and positive end-expiratory pressure (PEEP) to improve oxygenation and reduce lung injury.
- Supplemental Oxygen: To maintain adequate oxygen levels in the blood.
- Fluid Management: Careful administration of fluids to avoid fluid overload and worsening pulmonary edema.

2. Treating the Underlying Cause:
- Antibiotics: For bacterial infections or sepsis.
- Antivirals: For viral infections like COVID-19, if appropriate.
- Corticosteroids: To reduce inflammation, particularly in cases related to COVID-19 or autoimmune conditions.
- Supportive Care for Underlying Conditions: Managing conditions like pancreatitis or trauma that may contribute to ARDS.

3. Adjunctive Therapies:
- Prone Positioning: Placing patients in a prone position (face down) can improve oxygenation in severe cases of ARDS.
- Extracorporeal Membrane Oxygenation (ECMO): A form of advanced life support that provides oxygen to the blood outside the body and is used in severe cases when conventional ventilation is inadequate.

4. Preventive Measures:
- Preventing Complications: Such as ventilator-associated pneumonia or deep vein thrombosis (DVT).
- Rehabilitation: Long-term pulmonary rehabilitation may be necessary for patients recovering from ARDS.

Prognosis

The prognosis of ARDS depends on several factors, including the underlying cause, severity of the condition, and the patient's overall health. While many patients improve with appropriate treatment, ARDS can lead to long-term pulmonary and functional impairments. Mortality rates can be high, particularly in severe cases, and the recovery process can be prolonged. Early recognition and treatment are crucial for improving outcomes and reducing the risk of complications.

Acute Respiratory Distress Syndrome Epidemiological Insights
According to Delveinsight's estimates, among the 7MM, the United States has the highest number of ARDS incident cases with approximately 630,500 cases in 2021.
Request for sample pages @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Respiratory Distress Syndrome Treatment Market
Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS.
Other treatment options, to which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.
Promising Therapies in the Acute Respiratory Distress Syndrome Pipeline
EB05
Alteplase (Actilyse)
BIO-11006
ExoFlo (DB-001)
And others
Discover more about Acute Respiratory Distress Syndrome therapies in the pipeline @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Acute Respiratory Distress Syndrome Market
Edesa Biotech
Boehringer Ingelheim/Genentech
BioMarck Pharmaceuticals
Direct Biologics
And others
To understand key companies related to the Acute Respiratory Distress Syndrome Market, get a snapshot of the Acute Respiratory Distress Syndrome Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Acute Respiratory Distress Syndrome Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute Respiratory Distress Syndrome Companies: Edesa Biotech, Boehringer Ingelheim/Genentech, BioMarck Pharmaceuticals, Direct Biologics, and others
Key Acute Respiratory Distress Syndrome Pipeline Therapies: EB05, Alteplase (Actilyse), BIO-11006, ExoFlo (DB-001), and others
Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and emerging therapies
Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute Respiratory Distress Syndrome Market Access and Reimbursement
Table of Contents
1. Acute Respiratory Distress Syndrome Market Key Insights
2. Acute Respiratory Distress Syndrome Market Report Introduction
3. Acute Respiratory Distress Syndrome Market Overview at a Glance
4. Acute Respiratory Distress Syndrome Market Executive Summary
5. Disease Background and Overview
6. Acute Respiratory Distress Syndrome Treatment and Management
7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
8. Patient Journey
9. Acute Respiratory Distress Syndrome Emerging Drugs
10. 7MM Acute Respiratory Distress Syndrome Market Analysis
11. Acute Respiratory Distress Syndrome Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute Respiratory Distress Syndrome Market Drivers
15. Acute Respiratory Distress Syndrome Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Request for a sample report @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Trending Report by DelveInsight:

Bullous Pemphigoid Market | Congenital Myasthenic Syndromes Market | Cryopyrin-associated Periodic Syndrome Market | Glycogen Storage Disease Market | Inflammatory Breast Cancer Market | Lag-3-next Generation Immunotherapy Market | Metastatic Colorectal Cancer Market | Secondary Hyperparathyroidism Market | Dermatomyositis Market | Tenosynovial Giant Cell Tumors Market | C-met Non-small Cell Lung Cancer Market | Car T Cell Therapy for (NHL) Market | Esophageal Squamous Carcinoma Market | Failed Back Surgery Syndrome Market | Gingivitis Market | Neovascular Age-related Macular Degeneration Market | Nephrosclerosis Market |Netherton Syndrome Market | Noonan Syndrome Market | Pulmonary Sarcoidosis Market | Syncope Market | CAR T Cell Therapy for Multiple Myeloma Market | Chronic Spontaneous Urticaria Market | Malignant Pleural Mesothelioma Market | Candidemia Market | Chronic Thromboembolic Pulmonary Hypertension Cteph Market | Down Syndrome Market | Gene and Cell Therapies Targeting CNS Disorders Market | Interstitial Lung Disease Market | Sarcoidosis Market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.